Mabwell Achieves Global First with NMPA Acceptance of Novel LILRB4/CD3 Bispecific Antibody for Blood Cancers
核心洞察
China's NMPA has accepted the IND application for Mabwell (搜索)'s 6MW5311 (搜索), the world's first LILRB4 (搜索)/CD3 (搜索) TCE bispecific antibody to enter clinical development for hematologic malignancies.
The innovative therapy targets acute myeloid leukemia (搜索), chronic myelomonocytic leukemia (搜索), and multiple myeloma (搜索) using a unique steric hindrance design that enhances safety by activating T cells only in the presence of tumor cells.
Preclinical studies demonstrated potent cytotoxic activity across multiple tumor cell lines and achieved complete tumor clearance in high-expression AML models, with favorable safety profiles in primate studies.
Mabwell (搜索) (688062.SH) has achieved a significant regulatory milestone with China's National Medical Products Administration (NMPA) accepting the Investigational New Drug (IND) application for 6MW5311 (搜索), marking the world's first LILRB4 (搜索)/CD3 (搜索) T Cell Engager (TCE) bispecific antibody to advance into clinical development. The innovative therapy targets three challenging hematologic malignancies: Acute Myeloid Leukemia (搜索) (AML), Chronic Myelomonocytic Leukemia (搜索) (CMML), and Multiple Myeloma (搜索) (MM).
Novel Mechanism Addresses Safety Concerns
The 6MW5311 (搜索) antibody employs a sophisticated "2+1" asymmetric molecular structure that simultaneously targets LILRB4 (搜索) and CD3 (搜索), forming an immunological synapse between tumor cells and T cells to activate targeted tumor killing. What sets this therapy apart is its unique steric hindrance design, which significantly reduces CD3 antibody binding to T cells when tumor cells are absent. This mechanism ensures T cells are specifically activated only in the presence of tumor cells, substantially enhancing safety while improving anti-tumor efficacy.
Promising Preclinical Results
In vitro studies have demonstrated that 6MW5311 (搜索) exhibits potent cytotoxic activity across multiple tumor cell lines and patient-derived samples. The therapy's effectiveness was further validated in vivo, where pharmacodynamic studies showed significant tumor inhibition in both LILRB4 (搜索)-high and LILRB4-low expressing AML tumor models. Notably, the treatment achieved complete tumor clearance in high-expression models. Safety evaluation in cynomolgus monkey models revealed a favorable safety profile, supporting the therapy's clinical development potential.
Addressing Critical Unmet Medical Needs
The development of 6MW5311 (搜索) addresses significant gaps in current treatment options for blood cancers. While TCE technology has demonstrated clinical value in lymphoma indications with multiple approved products, no TCE therapies have been approved for AML or CMML. Current treatments for these conditions remain limited to chemotherapy, hematopoietic stem cell transplantation, and targeted therapies for specific mutations.
AML represents a particularly challenging malignancy, characterized by high heterogeneity and mortality. Globally, approximately 172.4 thousand new AML cases were diagnosed in 2022, with projections reaching 221.4 thousand by 2035, representing a compound annual growth rate of 1.94%. In China, approximately 30.8 thousand new AML cases were diagnosed in 2022, accounting for 17.9% of the global total, with expectations to reach 36.7 thousand by 2035.
CMML presents additional challenges as a rare disease with an annual incidence of approximately 3-4 per 100,000. This clonal hematopoietic stem cell disorder shares features with both myelodysplastic syndrome and myeloproliferative neoplasm, carrying an inherent risk of transformation to AML in approximately 15-20% of patients within 3-5 years. Currently, CMML lacks effective treatment options.
Global Development Strategy
Mabwell (搜索)'s development strategy extends beyond China, with the U.S. IND application currently in the pre-IND phase. The company plans to formally submit the application to the FDA in the second quarter of 2026, positioning 6MW5311 (搜索) for global clinical development. This timeline reflects the therapy's broad prospects for clinical development and significant market potential across multiple jurisdictions.
Multiple Myeloma Target
The inclusion of Multiple Myeloma (搜索) in 6MW5311 (搜索)'s development program addresses another area of significant medical need. MM accounts for approximately 1%-2% of all cancers and about 10% of hematologic malignancies globally. Despite improvements in patient survival rates over the past two decades through proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, MM remains largely incurable, with most patients experiencing multiple relapses during the disease course.
The median age at diagnosis is approximately 69 years, with higher incidence rates observed in males and individuals of African descent. The disease is characterized by uncontrolled proliferation of monoclonal plasma cells in bone marrow, leading to overproduction of abnormal immunoglobulins and subsequent end-organ damage, including hypercalcemia, renal impairment, anemia, and bone lesions.
Mabwell (搜索)'s achievement with 6MW5311 (搜索) represents a significant advancement in bispecific antibody technology, potentially offering new hope for patients with these challenging blood cancers while establishing the company as a pioneer in LILRB4 (搜索)/CD3 (搜索) TCE therapy development.